Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreCePRA)
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PreCePRA
- 08 Nov 2017 Interim results (n=50) assessing brain activity associated to arthritis measured by functional magnetic resonance imaging, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 17 Jun 2017 Interim analysis results (n=50) presented at the 18th Annual Congress of the European League Against Rheumatism
- 16 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.